Ablynx
Zwijnaarde
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $498.8M
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2017)
- Ticker: ebr:ABLX
- Website: ablynx.com
- Phone: (092) 620-000_
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ablynx-187158 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.